Inhibition of epithelial-to-mesenchymal transition (EMT) in cancer by nitric oxide: Pivotal roles of nitrosylation of NF-κB, YY1 and snail

Forum on Immunopathological Diseases and Therapeutics

Volumn 3, Issue 2, 2012, Pages 125-133

  Bonavida, Benjamin ^a   Baritaki, Stavroula ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epithelial to mesenchymal transition (EMT); Metastasis; Nitric oxide; Raf kinase inhibitor protein; Yin Yang 1

Indexed keywords

1 [2 (2 AMINOETHYL) N (2 AMMONIO ETHYL)AMINO]DIAZEN 1 IUM 1,2 DIOLATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE; NITRIC OXIDE DONOR; PROTEIN P50; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR YY1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CONFERENCE PAPER; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METASTASIS; NEOPLASM; NITROSYLATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN FUNCTION; TUMOR XENOGRAFT;

GASTROPODA;

EID: 84872358903     PISSN: 21518017     EISSN: 21518025     Source Type: Journal    
DOI: 10.1615/ForumImmunDisTher.2012006065     Document Type: Conference Paper

References (43)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
2. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12:895-904. (Pubitemid 44175140)
3. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741-4751.
4. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941-2953. (Pubitemid 29415256)
5. new treatments and novel insights into an old problem. Br J Cancer. 2008;99:387-391.
6. DeClerck K, Elble RC. The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci. 2010;15:213-225.
7. Acloque H, Thiery JP, Nieto MA. The physiology and pathology of the EMT Meeting on the epithelial-mesenchymal transition. EMBO Rep. 2008;9:322-326.
8. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-890.
9. Bonavida B, Baritaki S. Dual role of NO donors in the reversal of tumor cell resistance and EMT: downregulation of the NF-kB/Snail/YY1/RKIP circuitry. Nitric Oxide. 2011;24:1-7.
10. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol. 2001;153:1049-1060.
11. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131-142. (Pubitemid 43278296)
12. LaBonne C, Bronner-Fraser M. Snail-related transcriptional repressors are required in Xenopus for both the induction of the neural crest and its subsequent migration. Dev Biol. 2000;221:195-205. (Pubitemid 30253584)
13. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 2002;3:155-166.
14. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429-1437.
15. Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y, Bonavida B. The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF- κB/Snail/RKIP/PTEN circuit. Genes Cancer. 2010;1:409-420.
16. Wu K, Bonavida B. The activated NF-kappaB-Snail-RKIP circuitry in cancer regulates both the metastatic cascade and resistance to apoptosis by cytotoxic drugs. Crit Rev Immunol. 2009;29:241-254.
17. Bartitaki S, Bonavida B. Nitric oxide inhibits tumor cell metastasis via dysregulation of the NF-kB/Snail/RKIP loop. In: Bonavida B, ed. Nitric Oxide and Cancer: Prognosis, Prevention, and Therapy (Cancer Drug Discovery and Development). New York: Springer; 2010. p. 209-236.
18. Wink DA, Vodovotz Y, Cook JA, Krishna MC, Kim S, Coffin D, DeGraff W, Deluca AM, Liebmann J, Mitchell JB. The role of nitric oxide chemistry in cancer treatment. Biochemistry (Mosc). 1998;63:802-809. (Pubitemid 128588109)
19. Xie K, Huang S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic Biol Med. 2003;34:969-986. (Pubitemid 36398557)
20. Williams EL, Djamgoz MB. Nitric oxide and metastatic cell behavior. Bioessays. 2005;27:1228-1238. (Pubitemid 43076165)
21. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumor progression. Nat Rev Cancer. 2006;6:521-534. (Pubitemid 43980541)
22. Wink DA, Ridnour LA, Hussain SP, Harris CC. The reemergence of nitric oxide and cancer. Nitric Oxide. 2008;19:65-67. (Pubitemid 351970245)
23. Min C, Eddy SF, Sherr DH, Sonenshein GE. NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem. 2008;104:733-744. (Pubitemid 351830825)
24. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest. 2004;114:569-581. (Pubitemid 39572107)
25. Shin SR, Sanchez-Velar N, Sherr DH, Sonenshein GE. 7,12-dimethylbenz(a) anthracene treatment of a c-rel mouse mammary tumor cell line induces epithelial to mesenchymal transition via activation of nuclear factorkappaB. Cancer Res. 2006;66:2570-2575.
26. Baritaki S, Huerta-Yepez S, Sahakyan A, Karagiannides I, Bakirtzi K, Jazirehi A, Bonavida B. Mechanisms of nitric oxide-mediated inhibition of EMT in cancer: inhibition of the metastasis-inducer Snail and induction of the metastasis-suppressor RKIP. Cell Cycle. 2010;9:4931-4940.
27. Hongo F, Huerta-Yepez S, Vega M, Garban H, Jazirehi A, Mizutani Y, Miki T, Bonavida B. Inhibition of the transcription factor Yin Yang 1 (YY1) activity by S-nitrosylation. Biochem Biophys Res Commun. 2005;336:692-701. (Pubitemid 41267281)
28. Wu Y, Zhou BP. Snail: more than EMT. Cell Adh Migr. 2010;4:199-203.
29. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol. 2002;3:155-166.
30. Beach S, Tang H, Park S, Dhillon AS, Keller ET, Kolch W, Yeung KC. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene. 2008;27:2243-2248. (Pubitemid 351483382)
31. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, Del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2:76-83.
32. Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B. Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res. 2009;69:8376-8385.
33. Baritaki S, Chapman A, Yeung K, Spandidos DA, Palladino M, Bonavida B. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction. Oncogene. 2009;28:3573-3585.
34. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006;25:1125-1142.
35. Baritaki S, Katsman A, Chatterjee D, Yeung KC, Spandidos DA, Bonavida B. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 upregulation. J Immunol. 2007;179:5441-5453.
36. Palmer MB, Majumder P, Cooper JC, Yoon H, Wade PA, Boss JM. Yin yang 1 regulates the expression of snail through a distal enhancer. Mol Cancer Res.2009;7:221-229.
37. Notarbartolo M, Giannitrapani L, Vivona N, Poma P, Labbozzetta M, Florena AM, Porcasi R, Muggeo VM, Sandonato L, Cervello M, Montalto G, D'Alessandro N. Frequent alteration of the Yin Yang 1/Raf-1 kinase inhibitory protein ratio in hepatocellular carcinoma. OMICS. 2011;15:267-272.
38. de Nigris F, Rossiello R, Schiano C, Arra C, Williams-Ignarro S, Barbieri A, Lanza A, Balestrieri A, Giuliano MT, Ignarro LJ, Napoli C. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesis and metastasis. Cancer Res. 2008;68:1797-1808. (Pubitemid 351416565)
39. Odabaei G, Chatterjee D, Jazirehi AR, Goodglick L, Yeung K, Bonavida B. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Adv Cancer Res. 2004;91:169-200. (Pubitemid 39140959)
40. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, Fee F, Katsanakis KD, Rose DW, Mischak H, Sedivy JM, Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature. 1999;401:173-177. (Pubitemid 29436321)
41. Yeung KC, Rose DW, Dhillon AS, Yaros D, Gustafsson M, Chatterjee D, McFerran B, Wyche J, Kolch W, Sedivy JM. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol. 2001;21:7207-7217. (Pubitemid 32953475)
42. Fu Z, Smith PC, Zhang L, Rubin MA, Dunn RL, Yao Z, Keller ET. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst. 2003;95:878-889. (Pubitemid 36833879)
43. Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. Prostate. 2006;66:248-256. (Pubitemid 43191224)